Non-Canonical, Strongly Selective Protein Disulfide Isomerases as Anticancer Therapeutic Targets
Protein Disulfide Isomerases (PDIs) are emerging targets in anticancer therapy, with several PDI inhibitors demonstrating anticancer efficacy in preclinical models. Research has largely focused on “canonical” PDIs, such as PDIA1, which contain CXXC active site motifs where C represents Cysteine. Can...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2025-08-01
|
| Ráidu: | Biomolecules |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/2218-273X/15/8/1146 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|